Navigation Links
Amira Pharmaceuticals Announces Favorable Phase 1 Clinical Trial Results for Lead Product Candidate AM103 and Initiates Clinical Studies for the 2nd Entry Molecule for the Treatment of Respiratory and Cardiovascular Disease
Date:11/1/2007

SAN DIEGO, Nov. 1 /PRNewswire/ -- Amira Pharmaceuticals, Inc. announced completion of the company's Phase 1 clinical trial of AM103, Amira's internally discovered oral drug candidate for the treatment of inflammatory diseases linked to the leukotriene pathway. Amira also announced the start of a Phase 1 trial for AM803, a second oral drug candidate that targets the same inflammatory response.

AM103 and AM803 are novel inhibitors of 5-lipoxygenase-activiting protein (FLAP) that have demonstrated potential to treat asthma and cardiovascular disease (CVD) by preventing the synthesis of leukotrienes (LT), which trigger inflammation. The recently completed AM103 trial was designed to assess the safety and tolerability of an escalating single dose of the compound and escalating multiple doses in healthy volunteers who received AM103 or placebo for up to 11 days. The trial also assessed the pharmacodynamic properties of AM103, specifically its ability to inhibit LT production.

Results from the Phase 1 trial show that AM103 is safe and well-tolerated at doses up to 1,000 mg per day with no evidence of significant side effects. The systemic exposure of AM103 increased linearly from 50 mg to 1,000 mg.

Pharmacodynamic data demonstrated a robust and statistically significant reduction of LTB4 and LTE4 in a dose-dependent manner. "The results from this trial meet and even exceed our expectations for safety, and provide pharmacodynamic evidence consistent with this mechanism of action," said Peppi Prasit, Amira's chief scientific officer. "The half-life of up to 10 hours also gives us the opportunity to evaluate once-daily dosing in a Phase 2 trial, which we expect to start in 2008."

"Based on this very favorable profile, the excellent tolerability and the high levels of exposure obtained with oral dosing in Phase 1 studies, we are moving forward to conduct a Phase 2 study with AM103 in asthmatic patients," said Bob Baltera, Amira's chief executive
'/>"/>

SOURCE Amira Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Supply of Radiopharmaceuticals Hampered by Attacks
2. FDA approves Watson Pharmaceuticals Oxytrol patch
3. Ranbaxy Pharmaceuticals Inc awarded the prestigious outstanding supplier award received from Wal-Mart
4. Antigenics Pharmaceuticals plans for Phase III trial of its Melanoma vaccine
5. United Kingdom Is Lagging In Novelty In The Field Of Pharmaceuticals
6. Top Pharmaceuticals Influence Doctors Prescriptions
7. More Study On Side Effects of ADHD Drug Needed: Shire Pharmaceuticals
8. Personalized Medicine and Innovative Pharmaceuticals
9. New lease of life for asthmatics by Accentia Biopharmaceuticals
10. Pravastatin Launched by Watson Pharmaceuticals
11. Tata Industries picks up stake in Indigene Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... 2014 DoudouneCanadienneGoosePasCher.fr, one of the most ... recently unveiled its new selection of Trillium Parkas for ... that all these fashionable and comfortable items are available ... offer will last until September 01. , The ... new Canada Goose Trillium Parkas for new ...
(Date:8/21/2014)... The costs for maintaining pet health in the ... new insurance industry studies. The Quotes Pros company is helping owners ... plans from all 50 states at http://quotespros.com . , ... a routine visit or complex surgery can use the automated tool ... system will be asked to provide a zip code that can ...
(Date:8/21/2014)... MI (PRWEB) August 21, 2014 An ... informing a taxpayer that their federal tax payment is ... domain appears to come from the IRS, “tax@irs.gov”, it’s ... to provide personal and financial information. , While similar ... now, an uptick in phishing activity is occurring right ...
(Date:8/21/2014)... is a challenge. Thankfully, there are Zombies chasing you. , ... than 31,000 health and fitness apps on the market today, ... games to increase physical activity. , Gamification is currently the ... in to help people get fit. Whether or not it,s ... "It,s just been assumed that gamified apps will work, but ...
(Date:8/21/2014)... The University of Texas MD Anderson Cancer Center today ... of specialized breast screening at a network of community ... Starting in late November, MD Anderson will become the ... of Memorial Hermann,s 10 breast care centers, located in ... , Over time, the network will expand to Memorial ...
Breaking Medicine News(10 mins):Health News:Fashionable And Comfortable Canada Goose Trillium Parkas For Sale At DoudouneCanadienneGoosePasCher.fr 2Health News:Pet Insurance Finder for 50 States Launched at Insurance Website Online 2Health News:Beware Of Phony “Tax Payment Rejected” IRS Emails 2Health News:Playing hunger games: Are gamified health apps putting odds in your favor? 2Health News:MD Anderson and Memorial Hermann to operate breast screening network across Houston area 2
... the UK could be hit by a shortage of doctors. ... reforms mean stalling of their careers and withdrawal of consultant ... in England under Commissioning a Patient-led NHS has prompted some ... ,BMA public health doctors estimate as many as 100 public ...
... Men's Fitness magazine, and Chicago America's fattest. ,According to ... fittest cities behind Baltimore were Honolulu, Virginia Beach, Va., Tucson, ... Vegas, Los Angeles, Dallas and Houston, the magazine said. ... city on a list of Top 25. It climbed to ...
... and two in Van-have tested positive for the deadly H5N1 strain ... They are on treatment.// ,Turan Buzgan, head of the ... 28 people were tested at a government laboratory in Ankara. ... with H5N1, the most virulent form of the virus, since the ...
... survive in-hospital cardiac arrests than adults; with appropriate cardiopulmonary ... than previously thought.// ,These are some findings ... hospitals, supervised by Robert A. Berg, MD, professor of ... College of Medicine. ,The study results have ...
... University of Chicago have discovered an important mechanism used by ... of the brain that interprets visual signals.// ,In ... for a decades-old model of how neurons establish distant connections ... ,The research paper is published in the January 5, ...
... which result in global warming may result in biological, ... chemical composition of Nuttalides truempyi, which are tiny ancient ... Norris and Flávia Nunes belonging to the Scripps Institution ... part of the research. The samples were collected from ...
Cached Medicine News:Health News:After Cardiac Arrest, Children Fare Better Than Adults 2Health News:Chemical Signaling Helps Regulate Sensory Map Formation In The Brain 2Health News:Chemical Signaling Helps Regulate Sensory Map Formation In The Brain 3Health News:Earth Will Feel The Impact Of Global Warming 2
(Date:8/21/2014)... 2014 BreedIT Corp., (OTCQB: ... exclusive worldwide license holder and distributor of highly ... researchers, today is pleased to announce the formation ... Ltd, a leading Israeli medical Cannabis breeder. ... new breeds of medical Cannabis to meet the ...
(Date:8/21/2014)... FAIRFAX, Va. , Aug. 21, 2014 /PRNewswire/ ... real-time quality and Manufacturing Intelligence , today ... Intelligence Conference. The event will be held Oct. ... Mile, and is designed to showcase the necessity ... use of metrics and Manufacturing Intelligence to gain ...
(Date:8/21/2014)... 2014 CVS Caremark Corporation (NYSE: CVS ... and consideration payable in connection with its previously announced cash ... for (1) any and all of its 6.250% Senior Notes ... to a maximum amount of its 6.125% Senior Notes due ... due 2017 (collectively, the "Maximum Tender Offer Notes" and together ...
Breaking Medicine Technology:BreedIT Ltd. and Seach Ltd. Form KanaboSeed to Develop New Medical Cannabis Varieties 2BreedIT Ltd. and Seach Ltd. Form KanaboSeed to Develop New Medical Cannabis Varieties 3BreedIT Ltd. and Seach Ltd. Form KanaboSeed to Develop New Medical Cannabis Varieties 4InfinityQS to Host Manufacturing Intelligence Conference in Chicago 2CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 2CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 3CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 4CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 5CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 6
... Pharmaceuticals, Inc. (Nasdaq: ALXA ) announced today that ... Drug Administration (FDA or Agency) for the AZ-004 New Drug ... the meeting.  In December 2010, Alexza held the End-of-Review meeting ... October 2010.  A CRL is issued by FDA,s Center for ...
... The United States continues to lead the world in its ... , but emerging markets led by China, India and Brazil ... resources and activity overseas, according to a new PwC report ... . While the United States is expected to maintain its ...
Cached Medicine Technology:Alexza Pharmaceuticals Completes End-of-Review Meeting With FDA for AZ-004 (Staccato® Loxapine) NDA 2Alexza Pharmaceuticals Completes End-of-Review Meeting With FDA for AZ-004 (Staccato® Loxapine) NDA 3Alexza Pharmaceuticals Completes End-of-Review Meeting With FDA for AZ-004 (Staccato® Loxapine) NDA 4Alexza Pharmaceuticals Completes End-of-Review Meeting With FDA for AZ-004 (Staccato® Loxapine) NDA 5Alexza Pharmaceuticals Completes End-of-Review Meeting With FDA for AZ-004 (Staccato® Loxapine) NDA 6Emerging Markets Are Gaining Ground in Medical Technology Innovation; U.S. Maintains Lead, Finds PwC's Medical Technology Innovation Scorecard 2Emerging Markets Are Gaining Ground in Medical Technology Innovation; U.S. Maintains Lead, Finds PwC's Medical Technology Innovation Scorecard 3Emerging Markets Are Gaining Ground in Medical Technology Innovation; U.S. Maintains Lead, Finds PwC's Medical Technology Innovation Scorecard 4Emerging Markets Are Gaining Ground in Medical Technology Innovation; U.S. Maintains Lead, Finds PwC's Medical Technology Innovation Scorecard 5
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: